Clinical Stage Immunology Company - INmune Bio
 

 

Pipeline

Therapies that Target the INNATE IMMUNE Response

 

DN-TNF PlatformDisease FieldPre-clinicalPhase IPhase II (POC)PivotalEst. Next Milestone
Inmune Bio for Covid-19
QUELLOR™
COVID-19 Cytokin Storm
      P2 underway - data 2021
Inmune Bio for AD
XPRO1595™
NIH logo
Alzheimer's Disease CNS
      P2 Start Q4-2021
Inmune Bio for TRD
XPRO1595™
Treatment
Resistant Depression
      P2 Start Q4-2021

INB03 for treatment of MUC4 positive cancer and LIVNate for NASH Phase II trials begin after resolution of pandemic

NK-Priming PlatformDisease FieldPre-clinicalPhase IPhase II (POC)PivotalEst. Next Milestone
Inmune Bio for High-Risk MDS
INKmune™
Myelodysplastic Syndrome
ONCOLOGY
      P1 Mid-2021

INKmune for treatment of ovarian cancer Phase I trial begins after resolutions of pandemic

Have a Question?
858 964 3720
Email Us
dmoss@inmunebio.com
Opening Hours
M - F 8am to 5pm PST